Research Article - Biomedical Research (2017) Volume 28, Issue 19
Clinical effect of cyclophosphamide-taxinol therapy on breast cancer
Objective: This paper aims to discuss the clinical effect of cyclophosphamide-taxinol therapy in breast cancer.
Method: A total of 68 patients with breast cancer in our hospital from April 2013 to April 2016 were selected. Patients were randomly divided into observation and control groups. Each group consisted of 34 cases. The observation group was treated with cyclophosphamide-taxinol therapy. The control group was treated with taxinol-azithromycin therapy.
Results: Total therapeutic efficiencies of observation and control groups reached 38.23% and 7.65%, respectively, and showed a significant difference (P<0.05). The two groups also displayed a small difference prior to treatment (P>0.05). After treatment, vascular endothelial growth factor A (VEGFA) (82.51 ± 11.34) and VEGFB (77.95 ± 6.24) of observation group were significantly superior to those of the control group (P<0.05). CD4 (27.45 ± 5.48), CD8 (35.97 ± 7.16), CH4/CD8 (0.69 ± 0.18), and the number of natural killer cells (20.79 ± 2.49) of the observation group were significantly higher than those of the control group [(38.45 ± 5.98), (20.45 ± 6.41), (1.31 ± 0.48), and (39.44 ± 3.49), respectively]. The two groups showed statistically significant differences after treatment (P<0.05).
Conclusion: Cyclophosphamide-taxinol therapy can effectively reduce angiogenesis of patients with breast cancer and exert relatively ideal clinical effects. Therefore, this therapy should be further promoted in clinics.Author(s): Ling-Xin Meng, Jian Yu, Yu-Xiu Zheng, Cun-Ying Zhou, Zhao-Jun Ding